Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers

BACKGROUND: Chronic migraine is a complex clinical condition often undertreated. Onabotulinumtoxin A (OBT-A) was approved in Italy in 2013 for symptom relief in patients with chronic migraine who have failed, or do not tolerate, oral prophylactic treatments. However, the impact of OBT-A in clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Tassorelli, Cristina, Aguggia, Marco, De Tommaso, Marina, Geppetti, Pierangelo, Grazzi, Licia, Pini, Luigi Alberto, Sarchielli, Paola, Tedeschi, Gioacchino, Martelletti, Paolo, Cortelli, Pietro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493599/
https://www.ncbi.nlm.nih.gov/pubmed/28667550
http://dx.doi.org/10.1186/s10194-017-0773-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493599/
https://www.ncbi.nlm.nih.gov/pubmed/28667550
http://dx.doi.org/10.1186/s10194-017-0773-7

Ejemplares similares